We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Are Medical Stocks Lagging Amneal Pharmaceuticals (AMRX) This Year?
Read MoreHide Full Article
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is Amneal Pharmaceuticals (AMRX - Free Report) one of those stocks right now? Let's take a closer look at the stock's year-to-date performance to find out.
Amneal Pharmaceuticals is one of 1091 companies in the Medical group. The Medical group currently sits at #4 within the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. Amneal Pharmaceuticals is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for AMRX's full-year earnings has moved 23.6% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Based on the most recent data, AMRX has returned 101% so far this year. Meanwhile, the Medical sector has returned an average of -9.1% on a year-to-date basis. This shows that Amneal Pharmaceuticals is outperforming its peers so far this year.
Another Medical stock, which has outperformed the sector so far this year, is KalVista Pharmaceuticals, Inc. (KALV - Free Report) . The stock has returned 25.7% year-to-date.
For KalVista Pharmaceuticals, Inc. the consensus EPS estimate for the current year has increased 6.5% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Breaking things down more, Amneal Pharmaceuticals is a member of the Medical - Drugs industry, which includes 193 individual companies and currently sits at #94 in the Zacks Industry Rank. This group has lost an average of 14.1% so far this year, so AMRX is performing better in this area. KalVista Pharmaceuticals, Inc. is also part of the same industry.
Investors with an interest in Medical stocks should continue to track Amneal Pharmaceuticals and KalVista Pharmaceuticals, Inc. These stocks will be looking to continue their solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Are Medical Stocks Lagging Amneal Pharmaceuticals (AMRX) This Year?
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is Amneal Pharmaceuticals (AMRX - Free Report) one of those stocks right now? Let's take a closer look at the stock's year-to-date performance to find out.
Amneal Pharmaceuticals is one of 1091 companies in the Medical group. The Medical group currently sits at #4 within the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. Amneal Pharmaceuticals is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for AMRX's full-year earnings has moved 23.6% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Based on the most recent data, AMRX has returned 101% so far this year. Meanwhile, the Medical sector has returned an average of -9.1% on a year-to-date basis. This shows that Amneal Pharmaceuticals is outperforming its peers so far this year.
Another Medical stock, which has outperformed the sector so far this year, is KalVista Pharmaceuticals, Inc. (KALV - Free Report) . The stock has returned 25.7% year-to-date.
For KalVista Pharmaceuticals, Inc. the consensus EPS estimate for the current year has increased 6.5% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Breaking things down more, Amneal Pharmaceuticals is a member of the Medical - Drugs industry, which includes 193 individual companies and currently sits at #94 in the Zacks Industry Rank. This group has lost an average of 14.1% so far this year, so AMRX is performing better in this area. KalVista Pharmaceuticals, Inc. is also part of the same industry.
Investors with an interest in Medical stocks should continue to track Amneal Pharmaceuticals and KalVista Pharmaceuticals, Inc. These stocks will be looking to continue their solid performance.